GLOW Peptide Blend in Australia

Pre-blended GHK-Cu, BPC-157 and TB-500 for skin and repair research. GLOW is a three-peptide blend centred on GHK-Cu, with BPC-157 and TB-500 added for their repair and cell-migration mechanisms. It is built for skin and connective-tissue research where collagen signalling, inflammation control and cell migration all come into play together.

Dermal remodelling: collagen deposition and elasticity endpoints. Repair signalling: growth-factor and cytoskeletal pathways combined. Single-solution handling: a fixed ratio across three peptides. No trial has examined the blend as a single product. Each component carries its own literature, summarised on the individual compound pages. Researchers should regard GLOW as a fixed-ratio convenience rather than a validated combination.

Not tested as a single product. The evidence base is GHK-Cu's topical skin results, BPC-157's repair models and TB-500's migration data, each on its own page.

No combined data. The topical GHK-Cu record is solid; BPC-157 and TB-500 have no human safety studies.

In the published GLOW Peptide Blend research, the amounts used were 1 × 10⁻⁹ mol/L in cell culture, human dermal fibroblasts (ghk-cu) (Pollard JD et al. (2005)); 10 mg total, injection around the inflamed bladder area, Once, during a single procedure in human pilot, interstitial cystitis, n=12 (bpc-157) (Lee E et al. (2024)); 10 μg/kg bath (1 mL/rat) on the colon segment in rat, ischaemic colitis (bpc-157) (Duzel A et al. (2017)). These are the figures each study reports for its own model, listed in full in the dosage table on this page with links to PubMed. Peptide Aus supplies GLOW Peptide Blend for in-vitro research and does not give dosing guidance for people.

KLOW is GLOW plus KPV, the anti-inflammatory tripeptide, in a larger 80mg vial. Pick KLOW when inflammation control is part of the question.

GHK-Cu on its own isolates the copper-peptide effect; GLOW adds two repair peptides.

GHK-Cu, BPC-157 and TB-500. The 50mg vial carries 50mg total; the 70mg vial carries 70mg at the same ratio. The exact composition is on each batch certificate.

KLOW is GLOW with KPV, the anti-inflammatory tripeptide, added. Pick KLOW when inflammation control forms part of the research question.

With bacteriostatic water added slowly down the inside wall of the vial, then swirled gently. Each vial size lists its suggested volume, and the calculator converts volume to concentration.

Lyophilised: −20 °C, sealed, away from light and moisture. Reconstituted: 2–8 °C, used within 8–12 weeks, never frozen.

The Therapeutic Goods Administration (TGA) has not registered GLOW Peptide Blend as a medicine in Australia, and it is not approved for human or veterinary use. Peptide Aus supplies it only as a research reagent for in-vitro laboratory work. In Australia the supply of any substance for human use is governed by the Poisons Standard and the Therapeutic Goods Act, and the buyer is responsible for lawful use. If a treatment is what you want, speak to a doctor.

Directly from Peptide Aus, from Australian stock, in 2 vial sizes from $168.99 (50mg) to $199.99 (70mg). Prices are AUD and GST inclusive. Paid orders before 2pm AEST/AEDT dispatch the same business day, tracked.

It depends on the vial size: 50mg takes 3 mL, 70mg takes 3 mL. That gives 16.7 mg/mL, 23.3 mg/mL respectively. The reconstitution steps on this page and the calculator cover the rest.